Evidence map›Paper›PMID 39344086›Full record

ArticleJournal of psychopharmacology (Oxford, England)2024

Unidentified

Emma Y De Brabander, Thérèse van Amelsvoort, Roos van Westrhenen, GROUP Investigators

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of psychopharmacology (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Emma Y De BrabanderDepartment of Psychiatry and Neuropsychology, Mental Health and Neuroscience Research Institute, Maastricht University Medical Centre, The Netherlands.ORCID 0000-0002-0057-750X
Thérèse van AmelsvoortDepartment of Psychiatry and Neuropsychology, Mental Health and Neuroscience Research Institute, Maastricht University Medical Centre, The Netherlands.
Roos van WestrhenenDepartment of Psychiatry, Parnassia Groep BV, The Netherlands.
GROUP Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundResearch on the pharmacogenetic influence of hepatic

aimHere, we aimed to replicate the results of those studies in a Dutch cohort of patients with psychosis (

methodWe compared chlorpromazine-equivalent dose between

resultsWe found no relationship between chlorpromazine-equivalent dose and phenotype in any sample (complete sample:

conclusionClinicians were thus not intuitively adapting dose to

Indexed as

Antipsychotic AgentsCytochrome P-450 CYP2D6GenotypePsychotic DisordersRisperidoneAdolescentAdultChlorpromazineClozapineFemaleHumansMaleMiddle AgedNetherlandsPharmacogeneticsPhenotypeAntipsychotic AgentsChlorpromazineClozapineCytochrome P-450 CYP2D6RisperidoneCYP2D6drugs for psychosisPharmacogeneticspsychosis

Identifiers

PMID39344086
PMCPMC11528939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.